Receive The Newest Study Notifications

Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental GlomerulosclerosisTopline data from 36-week proteinuria endpoint anticipated in first quarter of 2021

by Lance Smith | Mar 10, 2020 | Study Scavenger Clinical Trial Recruitment Platform

SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) — Retrophin Inc. (NASDAQ: RTRX) today announced that the first 190 patients have been enrolled in the pivotal Phase 3 DUPLEX Study evaluating the safety and efficacy of sparsentan in focal segmental glomerulosclerosis...

FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)

by Lance Smith | Mar 10, 2020 | Study Scavenger Clinical Trial Recruitment Platform

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced receipt of approval from the Ethics Committee of the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in...

Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations

by Lance Smith | Mar 10, 2020 | Study Scavenger Clinical Trial Recruitment Platform

BOSTON–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today presented longer-term results from the DISCOVER trial of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets, F/TAF) for pre-exposure prophylaxis (PrEP), demonstrating...

Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis

by Lance Smith | Mar 10, 2020 | Study Scavenger Clinical Trial Recruitment Platform

WARREN, N.J., March 10, 2020 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the successful completion of its End-of-Phase 2 Meetings with the U.S. Food and Drug...

Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD

by Lance Smith | Mar 10, 2020 | Study Scavenger Clinical Trial Recruitment Platform

On track to report topline data mid-2020 BOSTON, March 10, 2020 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced achievement of full patient...

KalVista Pharmaceuticals – Oral Hereditary Angioedema Franchise Phase 2 Clinical Trials on Track –

by Lance Smith | Mar 10, 2020 | Study Scavenger Clinical Trial Recruitment Platform

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today...